FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2536705611> ?p ?o ?g. }

• W2536705611 endingPage "1511" @default.
• W2536705611 startingPage "1505" @default.
• W2536705611 abstract "BackgroundOur objective was to determine whether the choice of a HeartWare HVAD as opposed to a Heartmate II left ventricular assist device (HMII LVAD), impacts survival after heart transplantation after controlling for patient, donor, and center characteristics.MethodsWe queried the United Network for Organ Sharing (UNOS) database, which has recently made pretransplantation device duration available, for all adult patients undergoing bridge to transplantation (BTT) between January 2011 and March 2016. Recipient, donor, and transplant-specific characteristics were compared between patients receiving either device. Unadjusted survival was estimated with the Kaplan-Meier method. Risk-adjusted Cox proportional hazard models were constructed to determine the independent impact of device selection on mortality.ResultsThree thousand three hundred fifty-six patients who received the HMII and 1,051 patients who received the HVAD met inclusion criteria. Patients who received the HMII had a longer mean duration of VAD support (HMII, 429 days versus HVAD, 314 days; p < 0.001) but spent shorter periods on the waiting list (median, 190 days versus 232 days; p < 0.001). Patients who received the HMII had worse pre-LVAD renal function than did those who received the HVAD (glomerular filtration rate [GFR], 57 mL/min versus 62 mL/min, respectively; p = 0.001), but there was no difference in postoperative new-onset dialysis after transplantation (11.6% versus 10.5%, respectively; p = 0.14). There was no difference in unadjusted posttransplantation 30-day (95.5% versus 96.7%, respectively; log-rank p = 0.09), 6-month (91.8% versus 92.6%, respectively; p = 0.35), or 1-year (89.7% versus 90.9%, respectively; p = 0.22) survival between the 2 groups. After risk adjustment with Cox modeling, device selection did not predict mortality at any time point.ConclusionsAmong patients who received a BTT LVAD and then received a heart transplant, no survival differences were seen between patients initially implanted with an HVAD versus an HMII. Our objective was to determine whether the choice of a HeartWare HVAD as opposed to a Heartmate II left ventricular assist device (HMII LVAD), impacts survival after heart transplantation after controlling for patient, donor, and center characteristics. We queried the United Network for Organ Sharing (UNOS) database, which has recently made pretransplantation device duration available, for all adult patients undergoing bridge to transplantation (BTT) between January 2011 and March 2016. Recipient, donor, and transplant-specific characteristics were compared between patients receiving either device. Unadjusted survival was estimated with the Kaplan-Meier method. Risk-adjusted Cox proportional hazard models were constructed to determine the independent impact of device selection on mortality. Three thousand three hundred fifty-six patients who received the HMII and 1,051 patients who received the HVAD met inclusion criteria. Patients who received the HMII had a longer mean duration of VAD support (HMII, 429 days versus HVAD, 314 days; p < 0.001) but spent shorter periods on the waiting list (median, 190 days versus 232 days; p < 0.001). Patients who received the HMII had worse pre-LVAD renal function than did those who received the HVAD (glomerular filtration rate [GFR], 57 mL/min versus 62 mL/min, respectively; p = 0.001), but there was no difference in postoperative new-onset dialysis after transplantation (11.6% versus 10.5%, respectively; p = 0.14). There was no difference in unadjusted posttransplantation 30-day (95.5% versus 96.7%, respectively; log-rank p = 0.09), 6-month (91.8% versus 92.6%, respectively; p = 0.35), or 1-year (89.7% versus 90.9%, respectively; p = 0.22) survival between the 2 groups. After risk adjustment with Cox modeling, device selection did not predict mortality at any time point. Among patients who received a BTT LVAD and then received a heart transplant, no survival differences were seen between patients initially implanted with an HVAD versus an HMII." @default.
• W2536705611 created "2016-10-28" @default.
• W2536705611 creator A5050556570 @default.
• W2536705611 creator A5054034179 @default.
• W2536705611 creator A5073259726 @default.
• W2536705611 creator A5078708353 @default.
• W2536705611 creator A5079110635 @default.
• W2536705611 creator A5080805528 @default.
• W2536705611 creator A5082805294 @default.
• W2536705611 creator A5084115468 @default.
• W2536705611 date "2017-05-01" @default.
• W2536705611 modified "2023-09-30" @default.
• W2536705611 title "Survival After Orthotopic Heart Transplantation in Patients Undergoing Bridge to Transplantation With the HeartWare HVAD Versus the Heartmate II" @default.
• W2536705611 cites W1605522892 @default.
• W2536705611 cites W1858312919 @default.
• W2536705611 cites W1930150472 @default.
• W2536705611 cites W1970088087 @default.
• W2536705611 cites W1975680936 @default.
• W2536705611 cites W2003449420 @default.
• W2536705611 cites W2003696590 @default.
• W2536705611 cites W2009678985 @default.
• W2536705611 cites W2010455021 @default.
• W2536705611 cites W2010798210 @default.
• W2536705611 cites W2018509517 @default.
• W2536705611 cites W2027796031 @default.
• W2536705611 cites W2028062305 @default.
• W2536705611 cites W2042249671 @default.
• W2536705611 cites W2044386487 @default.
• W2536705611 cites W2063593569 @default.
• W2536705611 cites W2086001845 @default.
• W2536705611 cites W2089079581 @default.
• W2536705611 cites W2097250702 @default.
• W2536705611 cites W2116454200 @default.
• W2536705611 cites W2124696586 @default.
• W2536705611 cites W2125046201 @default.
• W2536705611 cites W2128389615 @default.
• W2536705611 cites W2133811028 @default.
• W2536705611 cites W2139451369 @default.
• W2536705611 cites W2140157456 @default.
• W2536705611 cites W2147657707 @default.
• W2536705611 cites W2149651645 @default.
• W2536705611 cites W2149704793 @default.
• W2536705611 cites W2165719156 @default.
• W2536705611 cites W2167180463 @default.
• W2536705611 cites W2167296557 @default.
• W2536705611 cites W2287102289 @default.
• W2536705611 cites W2321289777 @default.
• W2536705611 cites W2798360545 @default.
• W2536705611 cites W986541010 @default.
• W2536705611 doi "https://doi.org/10.1016/j.athoracsur.2016.08.060" @default.
• W2536705611 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27765177" @default.
• W2536705611 hasPublicationYear "2017" @default.
• W2536705611 type Work @default.
• W2536705611 sameAs 2536705611 @default.
• W2536705611 citedByCount "32" @default.
• W2536705611 countsByYear W25367056112017 @default.
• W2536705611 countsByYear W25367056112018 @default.
• W2536705611 countsByYear W25367056112019 @default.
• W2536705611 countsByYear W25367056112020 @default.
• W2536705611 countsByYear W25367056112021 @default.
• W2536705611 countsByYear W25367056112023 @default.
• W2536705611 crossrefType "journal-article" @default.
• W2536705611 hasAuthorship W2536705611A5050556570 @default.
• W2536705611 hasAuthorship W2536705611A5054034179 @default.
• W2536705611 hasAuthorship W2536705611A5073259726 @default.
• W2536705611 hasAuthorship W2536705611A5078708353 @default.
• W2536705611 hasAuthorship W2536705611A5079110635 @default.
• W2536705611 hasAuthorship W2536705611A5080805528 @default.
• W2536705611 hasAuthorship W2536705611A5082805294 @default.
• W2536705611 hasAuthorship W2536705611A5084115468 @default.
• W2536705611 hasConcept C126322002 @default.
• W2536705611 hasConcept C141071460 @default.
• W2536705611 hasConcept C159641895 @default.
• W2536705611 hasConcept C164705383 @default.
• W2536705611 hasConcept C207103383 @default.
• W2536705611 hasConcept C2778198053 @default.
• W2536705611 hasConcept C2778774980 @default.
• W2536705611 hasConcept C2778849806 @default.
• W2536705611 hasConcept C2779326848 @default.
• W2536705611 hasConcept C2779978075 @default.
• W2536705611 hasConcept C2911091166 @default.
• W2536705611 hasConcept C44249647 @default.
• W2536705611 hasConcept C50382708 @default.
• W2536705611 hasConcept C71924100 @default.
• W2536705611 hasConceptScore W2536705611C126322002 @default.
• W2536705611 hasConceptScore W2536705611C141071460 @default.
• W2536705611 hasConceptScore W2536705611C159641895 @default.
• W2536705611 hasConceptScore W2536705611C164705383 @default.
• W2536705611 hasConceptScore W2536705611C207103383 @default.
• W2536705611 hasConceptScore W2536705611C2778198053 @default.
• W2536705611 hasConceptScore W2536705611C2778774980 @default.
• W2536705611 hasConceptScore W2536705611C2778849806 @default.
• W2536705611 hasConceptScore W2536705611C2779326848 @default.
• W2536705611 hasConceptScore W2536705611C2779978075 @default.
• W2536705611 hasConceptScore W2536705611C2911091166 @default.
• W2536705611 hasConceptScore W2536705611C44249647 @default.
• W2536705611 hasConceptScore W2536705611C50382708 @default.
• W2536705611 hasConceptScore W2536705611C71924100 @default.

• next